Skip to search formSkip to main contentSkip to account menu

CI-919

Known as: CI 919, CI919 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Enoxacin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
The in-vitro activities of four quinolone carboxylic acids against 423 clinical isolates of Gram-negative rods and staphylococci… 
1986
1986
In vitro antibacterial activity of enoxacin (CI-919).
Antibacterial activity of enoxacin was evaluated against more than 3,700 clinical isolates using the agar-dilution method and an… 
1985
1985
Enoxacin: a potent inducer of filamentous Escherichia coli cells (a note).
Enoxacin (CI-919; AT-2266), a new naphthyridine derivative was found to induce morphologic changes at very low concentrations in… 
1985
1985
[In vitro antimicrobial activity of CI-919 against gram-negative bacilli and Staphylococcus aureus isolated from various pathologies].
1984
1984
Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains
The in vitro activity of enoxacin (CI 919, AT 2266), a new oral quinolone carboxylic acid compound, was compared with those of… 
1983
1983
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound
We tested CI-919 (AT-2266), a nalidixic acid analog, against 555 gram-positive and gram-negative bacteria, using microbroth or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)